Brachytherapy for clinically localized prostate cancer

Seminars in Surgical Oncology

Volumn 18, Issue 1, 2000, Pages 45-51

  Ragde, Haakon ^a   Korb, Leroy ^a  

^a NORTHWEST HOSPITAL   (United States)

Author keywords

Biopsy; adenocarcinoma; Brachytherapy; Clinical staging; Disease free survival; Iodine palladium radioisotopes; Patient selection; Postoperative complications; Prostate specific antigen; Prostatectomy; Prostatic neoplasms; Quality of life; Radiotherapy dosage; Treatment failure; Treatment outcome

Indexed keywords

IODINE 125; PALLADIUM; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; BONE METASTASIS; BONE SCINTISCANNING; BRACHYTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033986407     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(200001/02)18:1<45::AID-SSU7>3.0.CO;2-1     Document Type: Review

References (25)

1. Farkas A, Schneider D, Perrotti M, et al: National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998;52: 444-449.
2. Barringer B: Radium in the treatment of carcinoma of the bladder and prostate. J Am Med Assoc 1917;68:1227-1230.
3. Flocks RH: Present status of interstitial irradiation in managing prostatic cancer. JAMA 1969;210:328-330.
4. Whitmore WF Jr, Hilaris B, Grabstald H: Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J Urol 1972;108:918-920.
5. Holm HH, Juul N, Pedersen FJ, et al: Transperineal 125iodine seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983;130:283-286.
6. Martinez A, Gonzalez J, Stromberg J, et al: Conformal prostate brachy therapy: initial experience of a phase I/II dose-escalating trial. Int J Radiat Oncol Biol Phys 1995;33:1019-1027.
7. Mate TP, Gottesman JE, Hatton J, et al: High dose-rate afterloading 192Iridiurn prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 1998;41:525-533.
8. Ragde H, Elgamal AA, Snow PB, et al: Ten-year disease-free survival after transperineal sonography-guided iodine-125 brachy-therapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma [Review], Cancer 1998;83:989-1001.
9. Bice WS Jr, Prestidge BR, Prete JJ, Dubois DF: Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate brachytherapy using 1251. American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys 1998;40:1237-1241.
10. Ragde H, Blasko JC, Grimm PD, et al: Brachytherapy for clinically localized prostate cancer: results at 7-and 8-year follow-up [published erratum appears in Semin Surg Oncol 1998;14:185]. Semin Surg Oncol 1997;13:438-443.
11. Frazier HA, Robertson JE, Humphrey PA, Paulson DF: Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 1993;149:516-518.
12. Zietman AL, Coen JJ, Shipley WU, et al: Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-645.
13. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035-1041.
14. Grado GL, Larson TR, Balch CS, et al: Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998;42:289-298.
15. Prestidge BR: Radioisotopic implantation for carcinoma of the prostate: does it work better than it used to?[Review]. Semin Radiat Oncol 1998;8:124-131.
16. Zeitlin SI, Sherman J, Raboy A, et al: High dose combination radiotherapy for the treatment of localized prostate cancer. J Urol 1998;160:91-96.
17. Battermann JJ, Zeijlemaker BY: [Iodine-125 implantation in localized prostate cancer; technique and results from 100 patients at the Academic Hospital, Utrecht]. Ned Tijdschr Geneeskd 1998;142: 1146-1151.(Dutch)
18. Polascik TJ, Pound CR, DeWeese TL, Walsh PC: Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis [Review]. Urology 1998; 51:884-890.
19. Stokes SH, Real JD, Adams PW, et al: Transperineal ultrasound-guided radioactive seed implantation for organ-confined carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997;37:337-341.
20. Catalona WJ, Smith DS: 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994;152(5 Pt 2):1837-1842.
21. Ohori M, Goad JR, Wheeler TM, et al: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994;152(5 Pt 2):1843-1849.
22. Partin AW, Pound CR, Clemens JQ, et al: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20:713-725.
23. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152(5 Pt 2):1826-1830.
24. Trapasso JG, deKernion JB, Smith RB, Dorey F: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 1994;152(5 Pt 2):1821-1825.
25. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152(5 Pt 2):1850-1857.